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Background: Non-alcoholic fatty liver disease (NAFLD) is caused by abnormal accumulation of lipids within liver
cells. Its prevalence is increasing in developed countries in association with obesity, and it represents a risk factor
for non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Since NAFLD is usually asymptomatic
at diagnosis, new non-invasive approaches are needed to determine the hepatic lipid content in terms of diagnosis,
treatment and control of disease progression. Here, we investigated the potential of magnetic resonance imaging
(MRI) to quantitate and monitor the hepatic triglyceride concentration in humans.
Methods: A prospective study of diagnostic accuracy was conducted among 129 consecutive adult patients
(97 obesity and 32 non-obese) to compare multi-echo MRI fat fraction, grade of steatosis estimated by histopathology,
and biochemical measurement of hepatic triglyceride concentration (that is, Folch value).
Results: MRI fat fraction positively correlates with the grade of steatosis estimated on a 0 to 3 scale by
histopathology. However, this correlation value was stronger when MRI fat fraction was linked to the Folch
value, resulting in a novel equation to predict the hepatic triglyceride concentration (mg of triglycerides/g of
liver tissue = 5.082 + (432.104 * multi-echo MRI fat fraction)). Validation of this formula in 31 additional patients
(24 obese and 7 controls) resulted in robust correlation between the measured and estimated Folch values.
Multivariate analysis showed that none of the variables investigated improves the Folch prediction capacity of
the equation. Obese patients show increased steatosis compared to controls using MRI fat fraction and Folch
value. Bariatric surgery improved MRI fat fraction values and the Folch value estimated in obese patients one
year after surgery.
Conclusions: Multi-echo MRI is an accurate approach to determine the hepatic lipid concentration by using our
novel equation, representing an economic non-invasive method to diagnose and monitor steatosis in humans.
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Non-alcoholic fatty liver disease (NAFLD) is triggered
by intra-hepatocellular accumulation of lipids (mainly
triglycerides) and affects up to 30% of the Western
population [1,2]. Its pathogenesis usually involves the
so-called metabolic syndrome linked to obesity, diabetes,
hypertension, hypertriglyceridemia and/or insulin re-
sistance. Although NAFLD generally presents a benign
course, it may progress to non-alcoholic steatohepatitis
(NASH) and to the development of cirrhosis and hepa-
tocellular carcinoma [2].
NAFLD is usually asymptomatic at diagnosis [3]. There-
fore, determination of the hepatic lipid content poses a
major challenge in terms of identification, treatment
and control of the disease progression [4]. Currently,
the standard procedure used to evaluate hepatic steatosis
is the histopathological examination of cross-liver sections
and the semi-quantitative estimation of the percentage
of hepatocytes (0% to 100%) containing macrovesicular
fat, which is graded on a 0 to 3 scale [5]. However, this is
an expensive and invasive practice that presents inherent
risks. Moreover, it only provides a two-dimensional estima-
tion of a particular biopsy and is subject to inter-individual
visual evaluation depending on the pathologist’s training,
which usually results in overestimation of the liver fat
content [6]. On the other hand, evaluation of steatosis
using computational image analysis of histology slides is
possible [7,8], but is not carried out routinely in clinical
practice. Therefore, it is essential to establish new non-
invasive approaches to accurately determine the hepatic
fat concentration, allowing the correct diagnosis and
monitoring of steatosis.
Magnetic resonance imaging (MRI) represents a potential
non-invasive technique for assessing hepatic steatosis in
three-dimensions [9]. It measures the proportion of the
mobile proton density of the liver that is attributable to
fat [10]. Increasing evidence, using fat-water phantoms
and/or histopathological semi-quantitative analysis of hep-
atic fat as reference standards, suggests that MRI may rep-
resent an accurate method to determine the hepatic lipid
content [10,11]. However, additional research is still needed
to validate this hypothesis and, more importantly, to test
the potential of MRI as a tool to determine the hepatic
triglyceride concentration (that is, Folch value).
The purpose of our prospective study of diagnostic ac-
curacy was to evaluate the potential of multi-echo MRI
to quantitate the hepatic triglyceride concentration.
Multi-echo MRI fat fractions were compared with the
hepatic steatosis determined by either histopathology or
biochemical methods in patients operated for morbid
obesity or who underwent liver surgery. Moreover, we
analyzed the role of multi-echo MRI to monitor steato-
sis in morbidly obese patients after bariatric surgery.
Our results indicate that multi-echo MRI is a precisemethod to determine the hepatic triglyceride concentration
utilizing a novel equation and may be routinely employed
in clinical practice to diagnose and monitor steatosis.
Methods
Patient selection and study design
We designed a prospective and cross-sectional single-site
study of diagnostic accuracy (from January 2009 to January
2014), which was approved by the Ethics Committee of the
Donostia University Hospital as defined by Spanish law and
European directives. An informed consent form approved
by the institutional review board was signed by all patients
before starting the study.
For the non-obese group, we included all consecutive
patients referred to our hospital during 2009 for hepatic
surgery due to different etiologies without underlying liver
disease. The inclusion criterion was a body mass index
(BMI) <35 kilograms per square meter.
On the other hand, we included all consecutive obese
patients referred to our hospital between 2010 and 2013
for bariatric surgery (gastric sleeve or gastric bypass) or
for partial liver resection due to metastatic liver disease
without underlying hepatic disease. The inclusion criterion
for obese patients was BMI ≥35 kilograms per square meter.
All the patients in this group ranged from 36 to 63 BMI
and were classified as obesity class II (BMI = 35 to 39.9) or
III (BMI ≥40) by the world health organization (WHO)
[12]. All obese patients undergoing bariatric surgery had
surgical indication for BMI ≥40 or BMI = 35 to 39.9 with
significant morbidity [12].
Multi-echo MRI was performed in all patients under
study the day before surgery, and a liver biopsy was ob-
tained at the same time as the bariatric or hepatic sur-
gery. Importantly, the MRI-biopsy period was less than
24 hours. Liver biopsies were processed for histopatho-
logical studies as well as for quantification of the hepatic
fat concentration measured by a lipid assay (see below).
Expert professionals involved in each quantification method
(that is, MRI, histopathology and lipid assay) performed the
analysis blindly.
A validation group with 31 additional patients (24 obese
and 7 non-obese) was also included between June 2013
and January 2014 to confirm the efficiency of our new for-
mula to predict the hepatic Folch value from multi-echo
MRI. Thus, multi-echo MRI before surgery as well as liver
biopsy at the moment of operation were obtained from
these patients to compare the measured (by Folch) and
the predicted (by MRI) liver triglyceride concentration.
Finally, the aforementioned obese patients received a
second multi-echo MRI one year after surgery in order to
quantitate and monitor steatosis. In addition, a multivari-
ate analysis (initial Folch estimated, total weight, weight
loss, age and gender) of multi-echo MRI fat fraction and
Folch estimated was performed.
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Gender and age were considered in all patients. Body
measurements included weight and standing height at the
moment of the liver biopsy. The BMI was calculated from
these values. The presence of associated diseases such as
diabetes, hyperlipidemia and obstructive sleep apnea was
checked in all patients. In addition, treatment with drugs
(that is, contraceptives, statins, immunosuppressives, anti-
depressants, nifedipines, hormones and paracetamol)
was also considered. Biological data for each patient
included hematological parameters, liver function tests
and lipid profiles.
Liver histology
Liver biopsies were double-blind examined by two ex-
pert liver pathologists. All biopsies were obtained from
a hepatic wedge in the left anterior liver. Tissue sam-
ples were fixed in 10% formalin solution and embedded
in paraffin. Sections 4 μm thick were routinely stained
with hematoxylin-eosin. Furthermore, liver steatosis was
reported as a semi-quantitative evaluation of the percent-
age of hepatocytes (0% to 100%) containing macrovesicu-
lar fat (that is, lipid droplets equal to or larger than the
size of the nucleus, often displacing the nucleus) or micro-
vesicular fat (that is, numerous small fat droplets sur-
rounding a centrally located nucleus). Results were
expressed in terms of fat percentage in hepatocytes
and ranged from 0 to 3 (that is, 0: no fat, 1: up to 33%
fat, 2: 33% to 66% fat, and 3: >66% fat) [13].
Hepatic lipid assay
The lipid concentration of the liver was determined ac-
cording to the method described by Folch et al. [14]. This
biochemical approach determines the triglyceride concen-
tration in liver samples (mg of triglyceride/g of liver tissue)
and was used as a gold standard (that is, reference method)
to compare with both MRI data and histology. This
method, with some minor modifications, continues to
be considered the classic and most reliable approach
for quantitatively extracting lipids [15]. Two experi-
enced researchers performed the Folch determinations
from liver biopsies without knowing any clinical data
or MRI/histological results.
Briefly, liver tissue was washed with saline solution to
eliminate any traces of blood and subsequently homoge-
nized with 2:1 chloroform/methanol solution. Samples were
then incubated at 50°C for 30 minutes and with 2 ml of
KCl 0.1 M to speed up the phase separation process; this
mixture was shaken for one minute. Samples were kept
for two hours at 4°C, and then centrifuged at 2,000 to
3,000 rpm for 20 minutes to facilitate the separation of the
upper phase (or aqueous methanol dragging) and the lower
phase (or chloroform phase) containing the lipids. Most of
the aqueous phase was removed and the chloroform phaseadjusted to a known final volume with chloroform. A
volume of 1 ml of the chloroform phase was trans-
ferred into a tube previously weighed and the solution
was evaporated by drying using a nitrogen stream. The
tube was weighed again and the amount of fat calcu-
lated by the gravimetric method. Finally, lipids were
dissolved in isopropanol and triglycerides measured by
spectrophotometry using a commercial kit from Spinreact
(SantEsteve de Bas, Spain).
Multi-echo magnetic resonance imaging
The multi-echo MRI technique to assess the tissue fat
content was performed as we have previously reported
in animal models [16]. Briefly, this method is based on
a three-dimensional multi-echo gradient sequence ac-
quired in axial orientation with 12 different echoes
(TE min = 1.04 ms, δTE = 0.78 ms, TE Final = 25.14 ms,
TR = 72 ms, Flip Angle = 25°, FOV 375/328 mm, matrix
resolution 232/129). Images were achieved for spectral
analysis of the MRI signal to distinguish between fat and
water content in each image pixel. The three-dimensional
acquisition (10 consecutive slices: slice thickness = 12 mm)
was performed in a single breath-hold of 20 seconds that
resulted in a final image of the whole liver anatomy. All the
acquisitions were carried out in a 1.5 T Achieva System
(Philips Healthcare, Best, The Netherlands). An integrated
quadrature body coil was used in obese patients to fit better
inside the scanner. For non-obese patients, images were
acquired using a 16-channel phased array coil maintain-
ing the same image parameters previously described in
the acquisition method.
Quantitative analysis of the images was performed
following a previously published methodology [16]. This
approach was implemented in an in-line PRIDE tool that
runs in a MR Work Station (Extended Work Space, Philips
Healthcare). Importantly, native multi-echo images were
not directly analyzed by the radiologist. The software
automatically generates the water and fat intensity maps,
the water and fat R2* (reciprocal of T2*) maps, and fat
fraction maps. Water and fat signal maps are then ana-
lyzed by the radiologist as a conventional parametric map
(region of interest (ROI) analysis) to calculate the final fat
fraction measured as a percentage. The analysis of three
ROIs was performed in the fat fraction maps manually
dressed in segment III, near to the lower border of the
liver, avoiding vascular vessels. The average of three mea-
sured fat fraction values was calculated for each patient to
provide the final fat fraction content. The radiologist was
not aware of other test results. Therefore, the data were
not subject to any bias.
Statistical analysis
Quantitative variables were expressed as mean ± standard
deviation and categorical variables as absolute and relative
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measure of dispersion of continuous data. We used the
Student t test for statistical comparisons between two
groups of normally distributed variables and Mann–
Whitney tests for non-parametric methods. The asso-
ciation of variables with the lipid content in liver tissue
(Folch and histology) was carried out by linear regression
analysis and Pearson correlation coefficient (r) in the case
of continuous variables, and by one-way analysis of variance
(ANOVA) for categorical variables (or non-parametric tests
when necessary).
We considered the Folch determination as the reference
test of the liver fat content. To measure the ability of MRI
to provide a quantitative liver fat content, we used a linear
regression model. All the variables showing a relation with
the Folch determination in the univariate analyses with a
P value lower than 0.20 were selected for a multivariate
model. Using a backwards stepwise linear model we
estimated their ability to contribute to improve Folch
prediction over the model with MRI alone.
We constructed a calibration graph for the validation
dataset and studied the relation between estimated and
measured Folch value using a linear regression model.Table 1 Clinical features of the population under study
Clinical characteristics Control group
(number = 32
Age (years) 60.9 ± 11.5
Weight (Kg) 71.9 ± 13.6
BMI (Kg/m2) 26 ± 4.5
Associated diseases and treatments
Diabetes 5 (15.63%)
Dyslipidemia 10 (31.25%)









AST (U/L) 26.8 ± 12.9
ALT (U/L) 31.8 ± 20
GGT (U/L) 53 ± 46.4
ALP (U/L) 99.9 ± 48.5
Triglycerides (mg/dL) 106.9 ± 54.1
Cholesterol (mg/dL) 190.6 ± 54.1
Liver triglyceride content – Biochemical assay (mg/g) 33.3 ± 28.3
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotranTo assess the effect of clinical parameters on liver fat
improvement as measured by MRI (difference between
initial MRI-estimated and final MRI-estimated liver fat
content), we used backwards stepwise linear regression.
Results were considered to be statistically significant at
P <0.05. Statistical analysis was performed using STATA®
SE v13 software (StataCorp. LP, Drive College Station,
TX USA).
Results
Clinical and biological human data
One hundred and twenty nine adult patients (52 men and
77 women) with a mean age of 50 years (50.2 ± 14.3) were
included in the study between January 2009 and January
2014 (Table 1). Patients were clustered in two groups: 1) a
control group that underwent liver surgery (n = 32), and 2)
a group of obese patients (n = 97). Patients in the control
group underwent partial liver resection for different
etiologies that justified the intervention during 2009,
that is, 22 metastases, 3 hepatocarcinomas, 1 cholangiocar-
cinoma, 3 adenomas and 3 hemangiomas. Among the obese
patients, 86 underwent bariatric surgery and 11 partial liver
resection between 2010 and 2013.)
Obese group
(number = 97)
P value Overall (number = 129)
46.7 ± 13.4 <0.0001 50.2 ± 14.3
120.7 ± 26.3 <0.0001 108.7 ± 31.8
44.6 ± 7.9 <0.0001 40 ± 10.8
28 (28.86%) N.S. 33 (25.58%)
36 (37.11%) 0.054 46 (35.66%)
32 (33%) <0.001 33 (25.6%)
3 (3.1%) N.S. 4 (3.1%)
17 (17.5%) N.S. 20 (15.5%)
5 (5.15%) N.S. 6 (4.65%)
11(11.34%) N.S. 13 (10.07%)
10 (10.3%) N.S. 10 (7.75%)
6 (6.18%) N.S. 7 (5.42%)
7 (7.21%) N.S. 9 (6.97%)
24.7 ± 12.9 N.S. 25.2 ± 12.9
32.7 ± 21.8 N.S. 32.4 ± 21.3
35.6 ± 29.3 N.S. 40.2 ± 35.3
71.6 ± 22.4 <0.01 79.7 ± 34.3
163.3 ± 154.8 <0.01 148.5 ± 137.8
200.8 ± 42.6 N.S. 198.2 ± 45.9
94.5 ± 57.1 <0.0001 79.3 ± 57.8
sferase; BMI, body mass index; GGT, gamma glutamyl transpeptidase.
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13.4 years) that was lower than that of the control
group (60.9 ± 11.5 years) (P <0.0001), since obesity was
observed in middle-aged persons, and the control group
involved liver surgery in older patients. On the other hand,
as expected, the group of obese patients showed increased
body weight (120.7 ± 26.3 versus 71.9 ± 13.6 Kg) and BMI
(44.6 ± 7.9 versus 26 ± 4.5 Kg/m2) compared to the control
group (P <0.0001 in both comparisons), as well as increased
obstructive sleep apnea (33% versus 3.1%; P <0.001), serum
triglycerides (163.3 ± 154.8 versus 106.9 ± 54.1 mg/dL;
P <0.01) and hepatic triglyceride content (94.5 ± 57.1
versus 33.3 ± 28.3 mg/g; P <0.0001). Finally, the sero-
logical levels of alkaline phosphatase (ALP) were de-
creased in the obese patients compared to controls
(71.6 ± 22.4 versus 99.9 ± 48.5 U/L; P <0.01).Figure 1 Histopathological examination of steatosis in obese and con
from patients with different degrees of liver steatosis (grades 0 to 3). B) Obese
patients who underwent liver surgery. The overall prevalence of hepatic ste
steatosis ≥1 at histopathological analysis).Obese patients showed increased hepatic steatosis
compared to controls by histopathological examination
The analysis of steatosis by histopathology showed
different degrees of hepatic fat content between the
obese and control group (Figure 1). A total of 53.12%
of patients in the control group had no hepatic fat,
34.38% showed mild, 9.38% moderate and 3.12% severe
macrovesicular steatosis. On the other hand, 11.34%
of patients with obesity had no hepatic fat, 31.96%
showed mild, 41.24% moderate and 15.46% severe macro-
vesicular steatosis. Overall, the prevalence of hepatic stea-
tosis in this study population was 78.29% (101 of 129
patients had macrovesicular steatosis ≥1 at histopatho-
logical analysis). Importantly, no adverse events associated
with the liver biopsy collection were reported in any
patient.trol patients. A) Representative images with hematoxylin-eosin staining
patients showed increased degrees of steatosis compared to non-obese
atosis in our study was 78.29% (101 of 129 patients had macrovesicular
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histopathological estimation of hepatic steatosis in humans
In all 129 patients under study, we evaluated the potential
correlation between the multi-echo MRI fat fraction and
the semi-quantitative analysis of liver steatosis by histo-
pathological measurement (Figure 2). Our data showed
that multi-echo MRI fat fractions positively correlate
with the grade of steatosis estimated by histopatho-
logical measurements (r = 0.77, r2 = 0.60; P <0.0001).
However, importantly, although significant differences
in the multi-echo MRI fat fraction values were found
between all the groups of patients graded on a 0 to 3 scale
of steatosis, there was intragroup variability in the MRI
scores (mean coefficient of variation (CV) = 70.6%, Figure 2).
Importantly, no adverse events associated with multi-echo
MRI were reported in any patient.
Correlation analysis between the histopathological
estimation of hepatic steatosis in humans and the
biochemical measurement of the hepatic lipid
concentration
We studied the potential correlation between the semi-
quantitative analysis of steatosis in human liver biopsies byFigure 2 Multi-echo MRI fat fractions positively correlate with the gra
A) Representative multi-echo MRI images showing different degrees of wa
MRI fat fractions positively correlate with the grade of steatosis estimated b
represent the values of each case. C) Multi-echo MRI fat fraction mean valu
variation; MRI, magnetic resonance imaging; Std. Dev, standard deviation.histopathology and the direct quantification of the hepatic
lipid concentration (that is, Folch value) (Figure 3). Our data
indicated that Folch values positively correlate with the
grade of steatosis estimated by histopathological measure-
ments (r = 0.71, r2 = 0.50; P <0.05). In this regard, significant
differences in the Folch values were found between histo-
logical grades 1, 2 and 3, but not between grades 0 and 1.
Moreover, importantly, there was intragroup Folch variabil-
ity in all four groups of steatosis determined histopathologic-
ally on a 0 to 3 scale (mean CV= 72.9%, Figure 3).Correlation analysis between multi-echo MRI fat fraction
and the biochemical measurement of the hepatic lipid
concentration
Next, we evaluated the potential correlation between the
multi-echo MRI fat fraction of human livers and the direct
quantitation of steatosis through the biochemical measure-
ment of the hepatic triglyceride concentration (Folch value)
(Figure 4A). Our results indicated that the multi-echo MRI
fat fractions positively correlate with the Folch values
(r =0.90, adjusted r2 = 0.81; P <0.0001) resulting in the
following equation:de of steatosis estimated by histopathological measurements.
ter and fat intensity, and fat fraction in different patients. B) Multi-echo
y histopathological measurements in human livers (n =129). Dots
es of each steatosis grading group (0 to 3 scale). CV, coefficient of
Figure 3 The hepatic triglyceride concentration (Folch) positively correlates with the grade of steatosis estimated by histopathological
measurements. A) Correlation between Folch values and the grade of steatosis estimated by histopathological measurements in human livers
(n =129). Dots represent the values of each case. B) Folch mean values of each steatosis grading group (0 to 3 scale). CV, coefficient of variation;
Std. Dev, standard deviation.
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Calculation of the hepatic fat concentration through the
multi-echo MRI fat fraction
The aforementioned equation was evaluated with a new
validation group of patients. Thus, 31 additional adult
patients (24 obese and 7 controls) underwent multi-echo
MRI, and their fat fraction was employed to predict their
hepatic fat concentration (Folch) by using the formula.
Next, these predicted Folch values were compared with
the direct biochemical measurement of the hepatic fat
concentration. Our data showed that the equation is able to
predict the hepatic triglyceride concentration with a strong
correlation between 1) the biochemically measured Folch
values and 2) the estimated Folch values obtained with the
formula (r2 = 0.98; P <0.0001) (Figure 4B).Univariate analyses of hepatic fat concentration and
multivariate evaluation of multi-echo MRI prediction
We tested the role of the different variables analyzed with the
Folch method (Tables 2 and 3). The univariate studies showed
that Folch values are lower in male than female patients, and
higher in patients with apnea (P <0.05 and P <0.0001, respect-
ively; Table 2). In addition, Folch values correlate nega-
tively with age (P <0.05; Table 3), and positively with BMI
(P <0.0001; Table 3), alanine aminotransferase (ALT), triglycer-
ides and cholesterol (P <0.05 for all three comparisons; Table 3).
On the other hand, the multivariate analysis indicated that these
variables do not improve the Folch predictive capacity
obtained by the aforementioned formula (data not shown).
Obese patients show increased steatosis compared to
controls by multi-echo MRI and Folch value, which is
improved after bariatric surgery
Finally, from the 97 obese patients, all who had liver resec-
tion (n = 11) and those who underwent bariatric surgery at
Figure 4 Multi-echo MRI fat fractions positively correlate with the hepatic triglyceride concentration. A) Correlation between the Folch
values and the multi-echo MRI fat fraction in human livers (n =129). Box includes the resultant equation that predicts the Folch values from
multi-echo MRI fat fractions. B) Calibration plot between the measured and estimated Folch values using the prediction formula
[Folch = 5.082 + (432.104 * multi-echo MRI fat fraction)]. Dots represent the values of each case. MRI, magnetic resonance imaging.
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multi-echo MRI one year after the operation in order to
quantitate steatosis. In this regard, since it is a prospective
study, 30 patients did not fulfill the requirement of a year
after bariatric surgery and had not undergone the secondmulti-echo MRI. Obese patients present increased liver stea-
tosis compared to controls using multi-echo MRI fat frac-
tion and Folch value (P <0.0001; Figure 5A, B, respectively).
However, in patients who underwent bariatric surgery
the multi-echo MRI fat fraction signal intensities and
Table 2 Univariate analysis of categorical variables in









Gender Men 52 66.98 50.99 <0.05
Women 77 87.68 60.98
Diabetes Yes 33 89.36 59.02 N.S.
No 96 75.87 57.36
Dislipemia Yes 46 92.61 61.12 0.05
No 83 71.96 54.97
Contraceptive Yes 4 59.75 38.11 N.S.
No 124 79.78 58.58
Statin Yes 20 102.23 87 N.S.
No 108 74.88 56.55
Immunosuppressive Yes 5 117.5 75.00 N.S.
No 123 77.6 56.12
Antidepressant Yes 12 113.02 85.78 N.S.
No 116 75.65 53.72
Nifedipine Yes 10 92.82 62.59 N.S.
No 118 78 57.79
Hormones Yes 7 86.71 60.62 N.S.
No 121 78.72 58.13
Paracetamol Yes 9 91.55 78.82 N.S.
No 119 78.22 56.51
Apnea Yes 33 116.48 59.4 <0.0001
No 96 66.55 51.75
Std. Dev., standard deviation.
Table 3 Summary of the univariate regression models
between continuous variables and the measured
Folch values
Continuous variables Constant Coefficient r2 P value
Age 122.28 −0.85 0.04 <0.05
Weight −4.59 0.77 0.18 <0.0001
Height 200.65 −0.74 0.01 N.S.
BMI −27.24 2.66 0.25 <0.0001
AST 67.79 0.44 0.01 N.S.
ALT 60.33 0.57 0.04 <0.05
GGT 84.74 −0.15 0.01 N.S.
ALP 92.32 −0.21 0.02 N.S.
Triglycerides 63.67 0.09 0.05 <0.05
Cholesterol 27.30 0.25 0.04 <0.05
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; BMI, body mass index; GGT, gamma glutamyl transpeptidase.
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creased (P <0.0001; Figure 6A-C). This effect was not
observed in obese patients who did not receive bariat-
ric surgery (Figure 6D-F). Multivariate analysis indicated
that the Folch value estimated before bariatric surgery
and the weight loss (kg) both improve the Folch esti-
mated one year after surgery (P <0.0001; Table 4). Initial
weight, gender and age do not correlate with the im-
provement of steatosis.
Discussion
The key findings reported here indicate that MRI is a
non-invasive technique able to quantitate the hepatic tri-
glyceride concentration in NAFLD. Our prospective data
from 129 adult patients demonstrated that multi-echo MRI
fat fraction strongly correlates (r =0.90/adjusted r2 = 0.81)
with the biochemical measurement of the hepatic lipid
concentration (that is, Folch value), resulting in a novel
equation: Folch (mg of triglycerides/g of liver tissue) =
5.082 + (432.104 * multi-echo MRI fat fraction). This
formula was afterwards validated in 31 additional adult
patients, showing a strong correlation between the Folch
measured and MRI-estimated Folch values (r2 = 0.98;
P <0.0001). In addition, multi-echo MRI fat fraction
positively correlates with the semi-quantitative meas-
urement of steatosis by histopathological examinations
(r = 0.77/adjusted r2 = 0.60), but the correlation values
were lower than those obtained when the multi-echo
MRI fat fraction was correlated with the Folch value.
These data, together with the correlation values between
Folch and semi-quantitative measurement of steatosis by
histopathological examinations (r = 0.71/adjusted r2 =
0.50), indicated that the latter is not an accurate method
to determinate the hepatic fat content, and the Folch
method should be used as an appropriate gold standard
for NAFLD. Folch prediction obtained by multi-echo MRI
was not improved when other variables were included
in the equation. Obese patients show increased steatosis
compared to controls using Folch-measured and MRI-
estimated values. Bariatric surgery was followed by a
decrease in liver fat content as estimated by MRI one year
after surgery, and a substantial part of this improvement is
explained by the measured Folch value before surgery and
the weight loss after surgery. Our data are consistent with
the notion that multi-echo MRI is a non-invasive tech-
nique that allows the appropriate estimation of the hepatic
fat concentration, and can be employed to diagnose and
monitor liver steatosis in humans.
Hepatic fat quantification is receiving increasing atten-
tion in clinical practice since the prevalence of steatosis
associated with obesity is dramatically affecting developed
countries [2,3]; moreover, it is also important for liver trans-
plantation since 30% or more fat content contraindicates
liver donation [17]. Therefore, it is essential to establish
Figure 5 Obese patients show increased steatosis by multi-echo MRI and Folch value. A) Multi-echo MRI fat fraction and B) Folch value
both revealed that obese patients have increased steatosis compared to controls. Mean values are indicated by bars and dots represent the values
of each case. MRI, magnetic resonance imaging.
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concentration accurately, allowing the correct diagnosis
and monitoring of steatosis. Up to now, there have been no
specific biochemical or serological tests able to diagnose
the presence of fatty liver, and even less, methods to quan-
titate the degree of liver steatosis [2]. The standard pro-
cedure is the histological estimation of the percentage of
hepatocytes containing macrovesicular fat [5], which pos-
sesses inherent invasive risks and is subject to the variabil-
ity of visual estimation between observers [9].
MRI and 1H MR spectroscopy (MRS) are currently con-
sidered the most promising and sensitive non-invasive
methods to assess the total liver fat content [4,18,19], being
postulated as potential screening tools for patients at risk of
developing NAFLD (that is, with obesity, insulin resistance,
type 2 diabetes and/or nutritional disorders) [3,16]. MRIcan be performed using gradient-echo chemical shift
imaging (Dixon method) as T1-weighted dual echo, triple
echo, or multi-echo [19]. However, it is important to take
into account that liver iron deposition is able to distort
local magnetic fields responsible for T2* shortening, and
may ultimately result in signal intensity loss. Given the
high prevalence of iron deposition in the liver and the
considerable variations of T2* of the liver with consequent
errors in the quantification of liver steatosis, T2* bias
cannot be considered negligible and must be taken into
account. In this regard, multi-echo techniques can easily
correct for T2* decay and, thus, should be used to give re-
liable results [19,20].
Some studies have recently evaluated the diagnostic po-
tential of MRI techniques (that is, two-point Dixon, three-
point Dixon, DUAL, Spin echo method and multi-echo
Figure 6 Bariatric surgery improves steatosis by multi-echo MRI and Folch estimation. In obese patients who underwent bariatric surgery
(n = 56) there was a decrease in the multi-echo MRI fat fraction signal intensities and the Folch value estimated one year after surgery compared
to patients who did not receive bariatric surgery (n = 11). A) Representative multi-echo MRI images showing reduction of the fat signal and fat
fraction in obese patients after bariatric surgery. In obese patients B) the multi-echo MRI fat fraction signal intensities and C) the Folch estimated
one year after surgery were reduced. D) Representative multi-echo MRI images showing no changes of the fat intensity and fat fraction in obese
patients who did not receive bariatric surgery. In obese patients who did not undergo bariatric surgery E) the multi-echo MRI fat fraction signal
intensities and C) the Folch estimated after one year were not reduced. Dots represent the values of each case. MRI, magnetic resonance imaging.
Table 4 Final multivariate regression analysis for the
MRI-estimated lipid content one year after surgery
Steatosis improvement Coefficient Std. Err. P value
Initial estimated Folch 0.78 0.06 <0.0001
Weight loss 0.68 0.13 <0.0001
Constant −40.41 7.79 <0.0001
R2 = 0.76. MRI, magnetic resonance imaging; Std. Err., standard error.
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sis. They compared MRI with semi-quantitative analysis of
steatosis by histopathological grading, showing different de-
grees of correlation [1,10,21-23]. It is important to remark
that the MRI-biopsy time interval is a key factor in improv-
ing the correlation score, since the hepatic fat content may
change over time. In this regard, best correlations were ob-
tained with a MRI-biopsy period of seven days or less [10].
Jiménez-Agüero et al. BMC Medicine 2014, 12:137 Page 12 of 14
http://www.biomedcentral.com/1741-7015/12/137Here, 129 adult patients were included in our prospective
study. Ninety seven patients were obese, a risk factor for
hepatic steatosis, and the other 32 were non-obese patients
with potential low grades of steatosis who underwent liver
resections for several etiologies but without underlying liver
disease. Our data indicate that multi-echo MRI fat fraction
positively correlates with the semi-quantitative meas-
urement of steatosis by histopathological examinations.
Importantly, the MRI-biopsy period in our study was
less than 24 hours, resulting in a robust interpretation
of the data from this large cohort of patients. However,
histopathological analysis of steatosis is not an adequate
gold standard for MRI or 1H MRS, since it is a two-
dimensional semi-quantitative technique susceptible to
inter-individual visual estimation [9]. In this regard, the
Folch method is considered the most reliable approach to
extract and quantitate lipids [24]. It gives three-dimensional
quantitation of the hepatic triglyceride content, thus being
an appropriate gold standard [9]. This methodology is not
frequently used in clinical practice since it destroys the tis-
sue and, therefore, it cannot be submitted for histological
analysis, meaning that important features, such as inflam-
mation, fibrosis or iron deposition, are not evaluated [9].
Our data showed that the histopathological estimation of
steatosis positively correlates with the Folch value, although
the correlation value was modest, indicating that the semi-
quantitative analysis of steatosis presents Folch variability.
All of these data indicate that the Folch method is the ap-
propriate three-dimensional approach to determine the
hepatic fat concentration and is the correct gold standard
for NAFLD.
We and others [16,25-27] have recently reported positive
correlations between MRI and Folch in animal models of
NAFLD. Thus, we found using experimental (n = 40) and
control (n = 10) rat groups that multi-echo MRI strongly
correlates with Folch (r2 = 0.87) [16]. There are no available
studies in the literature, except for a recent pilot study with
18 adult patients who underwent cholecystectomy for
symptomatic cholelithiasis [28], that compare the ana-
lysis of hepatic steatosis by MRI and the biochemical
quantification of triglycerides in human liver biopsies.
Our results from a larger cohort of adult patients showed
that multi-echo MRI fat fraction strongly correlates with
the Folch, resulting in a novel linear regression equation
to predict the hepatic triglyceride concentration from
multi-echo MRI fat fraction measurements. This formula
was afterwards validated in 31 additional patients, showing
strong correlation between the measured and estimated
Folch values. Thus, obese patients show increased steatosis
compared to controls using multi-echo MRI fat fraction
and Folch value, and bariatric surgery decreased steatosis in
these patients one year after operation. Although the best
method to check the accuracy of the developed equation
would be the Folch measurement 12 months after surgery,there are ethical problems due to inherent methodological
risks. In addition, the MRI-estimated Folch value ob-
tained before bariatric surgery and the weight loss (kg)
both positively correlate with the improvement of stea-
tosis one year after operation.
These data strongly suggest that MRI is a valuable
diagnostic tool not only to estimate the hepatic lipid con-
centration, but is also a non-invasive technique to
monitor the changes in steatosis occurring in liver tis-
sue. MRI software may automatically generate the fat
fraction and, by using our new formula, determine the
triglyceride concentration without any inter-observer
bias. In addition, multi-echo MRI is a more economic
approach than Folch measurement; thus, MRI costs
usually are not as much of those resulting from the
Folch technique, which include ultrasound-guided liver
biopsy and the triglyceride measurement. However,
these costs may vary between different hospitals and
countries. Overall, this new equation may represent an
innovative clinical tool to diagnose and monitor steato-
sis in patient groups with risk of developing NAFLD,
and may also help to discard liver donations of individ-
uals with high fat content.
Conclusions
Our results identify multi-echo MRI as an appropriate
non-invasive approach to predict the hepatic lipid con-
centration using our novel formula. Since multi-echo
software is usually available in MRI units, this may rep-
resent an economical non-invasive method to diagnose
and monitor steatosis in risk groups with obesity and/or
metabolic syndrome.
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